In early 2018, Complexa will test CXA-10’s effectiveness and safety in phase two clinical trials for two diseases – focal segmental glomeruloscleroses (FSGS) and pulmonary arterial hypertension.
In early 2018, Complexa will test CXA-10’s effectiveness and safety in phase two clinical trials for two diseases – focal segmental glomeruloscleroses (FSGS) and pulmonary arterial hypertension.